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ABSTRACT 
 
Background and Objectives 
Acute Myocardial Infarction is one of the leading causes of mortality and morbidity in 
India. The treatment of Acute myocardial infarction is based upon the time interval and 
availability of Primary PCI, Even now in many centres thrombolysis is the initial 
treatment of choice. Now there are a number of drugs for Thrombolysis but still 
Streptokinase is used in many of the centres because of the ease of availability and less 
cost. Simple and rapid measures are needed for timely assessment of quality of 
reperfusion therapy in acute STEMI 
 ST segment elevation resolution following thrombolysis is simple, non-invasive, 
accessible tool for the assessment of coronary reperfusion. Objective of the present study 
was to assess the efficacy of thrombolysis with respect to time interval in Acute STEMI 
patients with regard to symptom relief, resolution of ST-elevation on treatment with 
streptokinase. And also to predict short term outcome during hospital stay in terms of 
adverse events and mortality. 
Method:  
A total of 60 patients at their first episode of AMI admitted within 24 hours from the 
onset of chest pain were included in the study. Once diagnosis of STEMI made and 
thrombolytic therapy was given, all patients were categorized into 3 groups, categorized 
on duration from onset of chest pain to administration of thrombolytic therapy, Patients  
received thrombolytic therapy with 1.5 million IU of streptokinase in 100 ml of normal 
saline over 45 minutes,  
Group-I   -0 to 3 hours (27 patients) – 45%  
Group-II -3 to 6 hours (14 patients) – 23.33%  
Group-III -6-12 hours (19 patients) – 31.67% 
Based on percentage resolution of ST segment elevation at 90 min following therapy, 
patients were divided into three groups: > 70% resolution (complete resolution group), 
30%-70% (partial resolution group) and < 30% (no resolution group). All the patients 
were followed up for in-hospital complications and mortality,  
RESULTS 
Of 60 patients, 9 patients (15%) had < 30% ST resolution (no STR), 26 
patients (43.3%) had 30-70% ST resolution (partial STR), 25 patients (41.7%) had > 
70% ST resolution (complete STR). During hospital stay adverse events including 
death for no resolution group was 100%, for partial resolution group was 69.2% and 
for complete resolution group was 28%. 
CONCLUSION 
Patients with no resolution of ST segment 90 minutes following thrombolysis 
associated with more frequent adverse events and increased mortality compare to 
partial and complete resolution group. And patients thrombolyzed earlier had better 
results and less complications. 
KEY WORDS: Acute myocardial infarction;ST segment resolution; Thrombolysis 
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INTRODUCTION 
 
Thrombolysis therapy has been shown in randomized controlled trials to 
improve the natural history of acute myocardial infarction with approximate 
30% reduction in mortality. Non-invasive detection of reperfusion is an useful 
guide to future treatment. Resolution of ST segment elevation following 
thrombolytic therapy has been shown to be a simple and useful predictor of left 
ventricular function and clinical outcome. 
 
 
This study is an effort to study the patients with acute myocardial infarction 
comparing their ECG findings on admission and subsequently after 
thrombolysis. And the outcome of thrombolytic therapy in terms of mortality and 
morbidity during hospital stay. 
 
Acute myocardial infarction is a major scourage of our times. It assumes 
increasing importance as it affects people in the most productive period of their 
life. 
 
 
The mortality and morbidity caused by acute myocardial infarction are major 
public health concern in the industrialized world and also slowly becoming a 
leading cause of mortality in developing countries as infectious diseases began 
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to come under control with newer chemotherapeutic agents. Incidence in West 
has decreased due to the better care and treatment. 
 
Primary goal of therapy in ST elevation myocardial infarction has been to 
restore normal blood flow in the occluded epicardial coronary artery as rapidly 
as possible. Early and sustained patency of infarct related artery is necessary, to 
ensure optimal outcome of reperfusion therapy. So optimal goal of reperfusion 
therapy is to establish nutrient blood flow at tissue level. 
 
 
Reduction in ST segment elevation, relief from chest pain, early peaking of 
serum concentration of creatine kinase and reperfusion arrythmias are some of 
the non-invasive markers of reperfusion. 
 
Chest pain resolution and biochemical markers failed to satisfy the clinical 
necessities. In the last decade several observations led to ST segment 
elevation resolution as rapid, simple and inexpensive marker for assessing the 
success or failure of reperfusion therapy. 
 
 
Schroder K et al. commented that ST segment resolution as measured by two cut-
off points, one at 70% and other at 30% from start of thrombolysis significantly 
predicts enzymatic infarct size.1 
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Farrer M et al. suggested that previous studies have shown an association 
between each resolution of ST elevation after thrombolysis and improved 
coronary patency and clinical outcome.2 
 
 
Since 1987 Anthon K et al. work on critical role of coronary thrombosis in 
acute myocardial infarction has been confirmed. This provides the scientific basis 
for thrombolytic therapy, the advent of which has been the cause of much global 
excitement and revolutionized the treatment of AMI.3 
 
 
The thrombolytic agent available for clinical outcome in our study is 
streptokinase. 
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OBJECTIVES 
 
 
To assess the efficacy of thrombolytic therapy with IV streptokinase in Acute ST 
elevation Myocardial Infarction patients in terms of:  
 
 ST segment resolution after thrombolysis. 
 
 To compare the ST segment resolution who were thrombolyzed within different 
time intervals  
 
 To study ST segment resolution with its correlation to clinical outcome and 
early complication. 
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REVIEW OF LITERATURE 
 
HISTORICAL REVIEW: 
Although myocardial infarction is often depicted as a modern disease it was clearly 
recognized before the modern era. There were references to what could be 
recognized today as angina pectoris, myocardial infarction and sudden death in 
ancient Egyptian, Greek, Biblical and Thelmudic sources. William Heberden in 
1768 presented his classic description of angina pectoris in a lecture before the Royal 
College of Physicians and it was published in 177245. 
 
Caleb Parry, a physician in Bath read a paper on coronary disease to local medical 
society in 1788. An early personal description of myocardial infarction was given 
by John Hunter, Surgeon to St George Hospital, London, who himself experienced 
what was probably a myocardial infarction in 1773. The description of his 
subsequent autopsy describes the scarred areas in his heart. 
 
Adam Hammer, a physician in Monneheim, is credited with the first antemortem 
diagnosis of coronary thrombosis with an autopsy showing a clot in a coronary artery 
in 1898. 
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Sir William Osler in 1910, delivered a lecture to the Royal College of Physicians, 
which noted that he had found the condition to be more common amongst his 
private or upper class patients than the poorer classes he saw at St.Bartholomew’s 
hospital, noting also the tendency of the disease to have a familial disposition. 
He thus combined the modern etiological theories of the interaction between 
environment and genetics46. 
 
 
Acute myocardial infarction was considered universally fatal until it was 
 
James Herrick, a Chicago Physician who in 1912 described the clinical features of 
sudden obstruction of coronary arteries. He also described survival of patient 
after such an event47. 
 
Streptokinase, an exogenous activator of the fibrinolytic system was first described 
by Tillet and Garner in 1933. They discovered that a filtrate of beta-hemolytic 
strains of streptococcus could dissolve human thrombus48. 
 
 
Canine experiment by Tennant and Wiggens, in 1935 showed that temporary 
occlusion of a coronary artery resulted in localized myocardial dysfunction 
and that reperfusion of the affected area frequently resulted in complete 
recovery of muscle function49. 
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Sherry in 1954 subsequently described the interaction between 
streptokinase and the human fibrinolytic system, which resulted in the conversion of 
plasminogen to plasmin48. 
 
 
Selective coronary angiography was first performed by Mason Sones in 1957 and 
the angiogram is still considered the gold standard for the evaluation of coronary 
artery anatomy and pathology50. 
 
 
Ruegsegger et al51     in 1959 first demonstrated successful lysis of 
experimentally induced thrombi by intracoronary administration of fibrinolytic in 
dogs. 
 
 
Favaloro RG et al52 in 1971 developed first effective coronary bypass grafting 
using reversed saphenous veins. He also concluded that treating an acute MI with 
coronary bypass grafting within 6 hours of onset could reverse the effects of acute MI 
limit infarct size and improve MI postoperatively. 
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Kordenat and Kedzi in 1972 demonstrated that electrocardiographic and 
hemodynamic improvement occurred after successful intracoronary thrombolysis in 
dogs53. 
 
Berg and colleagues54 from Spokane, Washington in 1975 published one of the first 
papers advocating the use of CABG for the treatment of acute MI and showed the 
benefit of surgical intervention by decreasing mortality rates significantly when 
revascularization was accomplished in < 6 hours. 
 
 
Chazer ET et al55    in 1976 first reported immediate arteriographic 
recanalization following intracoronary injection of streptokinase during STEMI. 
 
 
Reimer KA et al56 in 1977 demonstrated in a canine model that occlusion of coronary 
artery is followed by a wave front of myocardial necrosis spreading from 
endocardium to the epicardium, with an inverse relation between the time to 
reperfusion and the ultimate size and extent of transmurality of the infarct. 
 
 
Rentrop and co-workers in 1979 demonstrated acute reperfusion of occluded 
infarcted arteries with intracoronary streptokinase57. 
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Dewood et al58 in 1980 studied 517 patients with acute infarct who underwent 
coronary arteriography and left ventriculography within 24 hours after the onset of 
symptoms. 90% of the patients had coronary thrombi within the first 4 hours and 
frequency fell to 54% between 12 and 24 hour after symptom onset. Thus, they 
identified thrombotic occlusion of an epicardial coronary artery as the usual 
proximate cause of transmural AMI in patients. 
 
 
Kloner et al59 in 1983 demonstrated in the dog that a rim of sub-epicardial 
myocardium could be salvaged when reperfusion occurred within 6 hours of 
coronary occlusion. 
 
 
Anderson et al60 in 1983 randomized 50 patients with chest pain of less than four 
hours duration and persistent ST-segment elevation, Intracoronary 
streptokinase treated patients had significant improvement in global ejection 
fraction 10 days after therapy. Reperfusion rate in streptokinase treated patients was 
79% with significant improvement in echocardiographic wall motion index and less 
loss of R-wave amplitude compared to control. A trend towards decreased 
mortality occurred in the streptokinse-treated group, but it did not reach statistical 
significance.  
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The Western Washington Randomized Trial conducted in 1983 evaluated the 
effects of intracoronary streptokinase in 250 patients to control. 
Recanalization was achieved in 68% of streptokinase group. 30 day mortality was 
reduced to 3.7% in streptokinase treated group as compared to 11.2% in control. 
The mortality at 6 month was 3.7% in streptokinase group as compared to 14.7% in 
control61. 
 
 
 
The Netherlands Interuniversity Cardiology Institute Trial in 1983 allocated 
264 patients to conventional treatment and 269 to intracoronary streptokinase. 
The last 117 were first treated with 500000 units of intravenous streptokinase. 
Time to treatment was 80 minutes faster than in the Western Washington trial and 
the recanalization rate was higher (79%). Mortality rate at 28 days were significantly 
reduced with streptokinase (5.9 versus 11.7%)62.  
 
 
Shoeder R et al63 in 1983 derived empirically the conventional dose of 1.5 million unit 
over 60 minutes for intravenous streptokinase. 
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Yusuf et al64 in their overview of 24 randomized intravenous streptokinase trials and 
9 intracoronary streptokinase trials in 1985 showed that IV treatment produced a 
highly significant 22% reduction in odds of death. There was an even larger 
reduction in the odds of reinfarction, and an absolute frequency of serious adverse 
effect to set against this that is much smaller than absolute mortality reduction. 
The apparent size of the mortality reduction in the IV trials was similar whether 
treatment began early (<6 hour) or late (generally 12-24 hours). 
 
The ISAM trial in 1986 randomized 1741 patients to intravenous  
streptokinase or control within six hours of symptom onset. Mortality at 21 days was 
6.3% in streptokinase treated group and 7.1% in placebo. Mortality was 5.2% and 
6.5% in streptokinase treated group and placebo respectively when treated <3 hours 
from symptom onset. Thus they concluded that beginning IV streptokinase early 
after the onset of myocardial infarction limits the size of the infarct regardless 
of its localization and however, there was only a trend towards reduced mortality at 
21 days65. 
 
 
In the GISSI study conducted in 1986, a total of 11806 patients were randomized 
to either intravenous streptokinase or control within 12 hours of symptom onset. 
At 21 days overall hospital mortality was 10.7% in streptokinase versus 13% in 
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control, an 18% reduction. The benefit was most striking in patients treated 
within 3 hours (relative risk 0.74) from symptom onset, it remained statistically 
significant in 3-6 hour group (0.80). A non-statistically significant reduction of 
mortality in 6 to 9 hour (0.87) group and this difference reversed in the 9 to 12 
hours group (relative rate 1.19) probably because numerator and denominator in 
the late treated group were very small producing unstable estimates66. 
 
 
 
 
The ISIS-2 trial in 1988 randomized 17187 patients within 24 hours of the onset of 
symptoms of suspected myocardial infarction to streptokinase, aspirin both or 
neither. Streptokinase alone reduced five week vascular mortality (9.2% versus 
12%) and the combination of aspirin plus streptokinase additionally reduced 
mortality (8% versus 13.2%). There was evidence of benefit even for patients 
treated late after pain onset odds reductions at 5-12 and 13-24 hours was 16% and 
21% for streptokinase alone, 32% and 38% for combination of streptokinase 
and aspirin67. 
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In ISIS-3 conducted in 1992,  patients were eligible if they were thought to be within 
24 hours of the onset of acute myocardial infarction and were randomly allocated to 
receive streptokinase, anistreplase and tissue plasminogen activator. All patients 
received aspirin and half were randomly allocated to subcutaneous heparin. There 
was no significant difference in survival at 35 days within any of the six possible 
treatment combination68. 
  
 
The EMERAS trial in 1993 found an insignificant 14% reduction (11.7% 
versus 13.2%) in hospital mortality in 2080 patients randomized to streptokinase or 
placebo 6-12 hours after symptom onset. Whereas there was little difference in 
hospital Mortality among the 1791 presenting after 13-24 hour (11.4% versus 
10.7%)69. 
 
 
 
The Late Assessment of Thrombolytic Efficacy (LATE) study in 1993 randomized 
5,711 patients with symptoms between 6 and 24 hours from onset to alteplase or 
placebo. A significant 26% reduction in 35 days mortality (8.9 versus 12%) was 
found in the 6-12 hours group. Rates were 8.7% and 9.2% respectively, for 
those treated at 12-24 hours but subgroup analysis of patients who were 
randomized promptly after admission and treated without any delay showed 
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benefit from thrombolysis throughout the 6-24 hours. Patients in this group 
treated within 12 hours of symptom onset had 30% reduction and those treated 
after 12 hour a reduction of 19% in mortality70.  
 
 
Fibrinolytic therapy trialists (FTT) collaborative group in 1994 over viewed 9 
trials which randomized patients with suspected acute myocardial infarction to 
fibrinolytic therapy or placebo. Among 45,000 patients randomized highly 
significant morality reduction of 30 per 1000 for 0-6 hours group, 20 per 1000 for 
7-12 hours group was observed. Statistically uncertain benefit of about 10 per 1000 
for 13-18 hours group noticed. This overview indicated that the gradual diminution 
in benefit with fibrinolytic therapy may be due to the association of later treatment 
with a larger excess of death71. 
 
 
Topol et al72 in 1992 randomized 197 patients with 6 to 24 hours of symptom 
onset to tissue plasminogen activator or placebo. Patients were again randomized 
to angioplasty or no angioplasty if found to have occluded infarct related artery on 
angiogram after 24 hour. Infarct vessel patency was achieved in 65% of tpA treated 
patients as compared to 27% in placebo. At 6 months infarct vessel patency was 
59% in both group but there was significant increase in end-diastolic volume with 
increased left ventricular cavity size in placebo group compared to thrombolyzed 
patients. 
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Igawa et al73 in 1993 categorized 22 patients with first acute anterior wall MI into 
four groups: 
 
 
Group-A (n=5): Patients who had with successful reperfusion within 6 hours. 
 
Group-B (n=6) patients with late patency of the infarct related artery, Group-C 
(n=6 patients) without recanalization out with good collaterals. Group-D (n=5 
patients) without recanalization and poor or no collaterals. The left ventricular size 
and function were preserved better in group-A than in others as evaluated by contrast 
left ventriculography.  
 
 
Although there was no difference in regional wall motion of the infarct area among 
group B, C and D. The EF was greater and the percentage perimetric 
circumference was smaller in groups B and C than in D. 
 
Also the left ventricular end-diastolic volume was greater in D, thereby 
suggesting that blood supply to the infarct area is essential for the preservation of left 
ventricular size and function regardless of the timing and route. 
 
 
Leoncini M et al74 in 1994 evaluated the effectiveness of late thrombolysis      (6-24 
hours) in 15 patients with pre and post treatment perfusion scintigraphy with TC-
99m sestambi.  
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7 patients with perfusion recovery (group-1) showed significant decrease in uptake 
score compared to 8 ptients with absent or minimal perfusion recovery after 
thrombolysis (group-II). Defect score further reduced in group-I patients along with 
decrease in asynergic score assayed by 2D echo significantly after 35 days 
compared to group II patients.  
 
Coronary angiogram performed 6-9 days showed patent vessel in all patients of 
group-I as compared to only 2 patients of group-II. EF increased from 38% to 
47% in group I as compared to unchanged 40% as assayed by gated blood pool 
imaging after 35 days. 
 Thus, it was demonstrated that it is still possible to obtain an effective reperfusion 
and the consequent salvage of jeopardized tissue demonstrated by recovery of 
both regional and global left ventricular function. 
 
 
 
Romero et al75 in 1996 randomized 21 patients with acute anterior wall MI presenting 
between 6 to 12 hours of symptom onset to streptokinase plus aspirin (n=12), or 
aspirin alone (n=9). Myocardial expansion evaluated by 2-D echo in terms of 
distortion area, distortion peak, septal thickness were present in 25% of 
thrombolyzed patients to 66.6% of placebo group. 
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Blood Supply of Heart,5 
 
The circulation of blood in the blood vessels that supply blood to and from the 
heart muscle itself is coronary circulation. Although blood is present in the 
chambers of the heart, the muscles of the heart are so thick that it a separate 
blood supply, these vessels which supply blood to the heart are called Coronary 
arteries and their counterpart which removes impure blood from the heart are called 
cardiac veins 
 
 
The heart is supplied by the left and the right coronary arteries. The left main 
coronary divides into the left anterior descending artery (LAD) and the left 
circumflex artery LCX. The Left Anterior Descending lies in the groove called the 
anterior interventricular groove, supplies the septum , anterior wall and apex of the 
left ventricle. The circumflex artery gives marginal branches that supply the lateral, 
posterior and inferior segments of the left ventricle.  
The right coronary artery ( RCA)- lies in right AV groove, it supplies RA, RV and 
postero-inferior part of LV. The posterior descending artery perfuses the posterior 
surface of the heart. 
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Left anterior descending coronary artery 
 
The Left Anterior Descending artery  supplies blood to the anterior wall 
especially via the diagonal branches (segments 1, 7, and 13), the anterior part 
of the septum via the septal branches (segments 2, 8, and part of 14; sometimes 
segment 14 is co-perfused by the Right Coronary Artery), and also the areas 3 and 
9 which are also co-perfused by Right Coronary Artery.  
 
Often the Left Anterior Descending artery supplies blood to apical portion of the heart 
and the inferior wall and the Left anterior descending artery winds around the apical 
portion of the heart in around 80% of subjects, sometimes the RBB is supplied by the 
initial septal branch. 5 
 
 
 
 
Right coronary artery 
 
Right Coronary artery supplies blood to the RV, the inferior part of the inter-
ventricular septum (areas 3 &9). Area 14 is perfused by Left Anterior Descending 
artery, but in some subjects it is perfused by either artery. The Right Coronary 
Artery also supplies blood to a major portion of the inferior wall (area 4, 10 and 
15). These areas 4 and 10 can also be supplied by the Left Circumflex artery,  
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Finally the Right Coronary Artery supplies blood to area 17 if the Left Anterior 
Descending is small, The Atrio-ventricular Node is supplied by the Posterior 
descending artery which is a branch of RCA.5 
 
 
Circumflex coronary artery 
The Left Circumflex artery supplies blood to lateral surface,  base of anterior 
wall (area 6), the middle and lower areas are  shared with the Left Anterior 
Descending (areas 12 and 16) and the whole part of  the lateral wall (area 5 and 
11) in the left dominant circulation. The LCX artery is dominant it supplies the 
major portion of the the inferior wall of the ventricle especially areas 4 and 10, 
rarely areas 15 and 17. 5 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1: Circumflex
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Figure 2: Coronary circ
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Third Universal Definition of Myocardial Infarction  
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Types of Myocardial Infarction  
 The Third Universal Definition of MI consensus group defines various types of 
MI it is as follows 
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Causes of Myocardial Infarction 
 
1. Congenital anomalies: 
a) Anomalous origin from the aorta. 
b) Single coronary artery 
c) Atresia of coronary ostium 
d) Osteal ridges 
e) Myocardial bridges 
 
2. Embolus: 
i) Natural 
ii) Tumour 
iii) Calcium 
iv) Vegetation 
v) Iatrogenic 
vi) Cardiac surgery 
vii) Prosthetic valves 
3. Dissection: 
a) Coronary artery 
b) Aortic 
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4. Trauma: 
a) Non-penetrating 
b) Penetrating 
c) Surgery 
 
5. Arteritis: 
a) Takayasu’s disease 
b) Polyarteritis nodosa 
c) Systemic lupus erythematosus 
d) Kawasaki syndrome. 
 
 
 
 
6. Metabolic disorders: 
a) Mucopolysaccharoidosis 
b) Homocystinuria 
c) Fabry’s disease 
d) Amyloid 
 
7. Intimal proliferation: 
a) Irradiation therapy 
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b) Fibromuscular hyperplasia 
 
8. External compression: 
a) Aortic aneurysm 
b) Tumor metastasis 
 
9. Thrombosis without underlying atherosclerotic plaque 
a) Polycythemia 
b) Thrombocytosis 
c) Hypercoagulability 
 
10. Substance abuse 
a) Cocaine 
b) Amphetamines 
 
11 Myocardial oxygen demand-supply disproportion 
a) Aortic stenosis 
b) Systemic hypertension 
 
11. Intramural coronary disease: 
a) Hypertrophic obstructive cardiomyopathy 
b) Neuromuscular 
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Thrombolytic Therapy8 
 
It will be discussed under the following 
 
1. Definition 
 
2. Characteristics, aims and objectives of fibrinolysis 
 
3. Classification and newer thrombolytic agents, comparative features  
   of newer agents. 
 
4. Guidelines 
 
5. Contraindications 
 
6. Clinical benefits of thrombolysis 
 
7. Complications 
 
8. Assessment of myocardial reperfusion 
 
9. Conjunctive Treatment 
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1. Definition8 
 
Thrombolytic can be defined as a substance which causes lysis of the thrombi to 
recanalize the occluded blood vessel.  
 
 
 
 
 
Thrombus can be defined as a mass of aggregated platelets adherent to the 
vessel wall and immobilized with fibrin. 
 
 
2. Characteristics - Objectives of Fibrinolysis8 
 
Thrombus is formed. The fibrinolytic system is activated so as to dissolve the 
thrombus and re-establish normal blood flow. Normally, thrombolysis is initiated 
by the release of intrinsic thrombolytic agents like tissue plasminogen or 
prourokinase.  
 
During the formation of thrombus large amount of plasminogen from the 
circulation is trapped in the thrombus. TPA released from the injured vascular 
endothelium converts this inactive plasminogen to plasmin. Plasmin digests the 
fibrin threads and thus dissolves the clot. 
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t-PA  Plasminogen  t-PD inhibitor 
 
                                            Plasmin  Antiplasmin 
 
    Lysin of Fibrin 
 
        Degradation products 
 
 
 
Though thrombolysis begins immediately after vascular injury, Clot lysis and 
vessel recanalization may not be complete upto 7-10 days. This process can 
be enhanced by exogenous extrinsic activator for therapeutic purpose. All 
thrombolytics act by activation of plasminogen to plasmin either 
directly/indirectly.  
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Objectives of Fibrinolysis 
 
 
1) To cause lysis of the thrombus within the occluded artery responsible for 
the damage. 
 
 
2) To cause decrease in plasma viscosity and red cell sludging by digestion 
of fibrinogen and high molecular weight fibrinogen-fibrin complexes. 
 
 
3) To cause lysis of thrombi in the coronary vessel adjacent to the infarct.  
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3. Classification and Newer Thrombolytic agents formulated (Blann AD et al.)8 
 
 
 
 
Source 
 
 
Streptokinase 
 
 
Urokinase 
 
 
APSAC 
 
 
t-PA 
 
From culture 
filtrate of 
streptokinase 
 
From 
human 
renal cell 
culture 
Complex of 
streptokinase 
human 
plasminogen 
Recombinant 
DNA 
technique 
 
 
Plasma binding 
 
Indirect 
 
Direct 
 
Indirect 
 
Direct 
 
Fibrin 
specificity 
 
Minimal 
 
 
Moderate 
 
 
Minimal 
 
 
Moderate 
  
Systemic lysis 
 
High 
 
High 
 
High 
 
Low 
 
Bleeding site 
 
High 
 
High 
 
High 
 
High 
 
Antigenicity 
 
Yes 
 
No 
 
Yes 
 
No 
 
Allergic state 
 
Yes 
 
No 
 
Yes 
 
No 
 
Acute coronary 
patency rate 
 
40-60% 
 
 
50-70% 
 
 
60-70% 
 
 
60-85% 
  
Metabolism 
 
Liver 
 
Liver 
 
Liver 
 
Renal 
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Summary of Thrombolytic Agents in Clinical Practice of Clinical Trails8 
Agents 
 
 
Comments 
 
 
 
First-generation 
Streptokinase 
 
 
Plasma half-life 18-25 min; patency at 90 min is 40%, and 32% 
achieve TIMI-3 flow; incidence of intracerebral hemorrhage 
about 0.3%; antigenic and therefore not used within 5 days to 2 
years after prior administration; about 25 lives saved per 1.000 
treated. Dose 1.5 million units over 1 hour intravenously. 
 
 
Urokinase 
 
 
Plasma half-life 15 min;not considered antigenic; administration as 
1.5 million units intravenous bolus, followed by 1.5 million units 
over 90 minutes. 
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Anisoilated 
plasminogen 
streptokinase activator 
complex 
 
 
Plasma half-life 100 minutes; patency at 90 minutes is 63%, and 
43% achieve TIMI-3 flow; incidence of intracerebral 
haemorrhage is 0.6%; antigenic; about 25 lives saved per 1.000 
treated; dose: 30 mg over 5 minutes intravenously. 
 
 
Second-generation 
Tissue-type 
Plasminogen activator 
rt-PA (one chain), 
t-PA (two chain), alte-
plase (by recombinant 
technology) 
 
 
Plasma half-life 5 minutes. 
Plasma half-life 5 minutes; no antigenicity and causes moderate 
systemic fibrinogen depletion; about 35 lives saved per 1,000 
treated; dose: 1) accelerated t-PA: administered as 15-mg bolus 
intravenously, then 50 mg over 30 min, and 35 mg over the 
next 60 minutes; 2) 100 mg over 90 minutes intravenously. 
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Single-chain urokinase 
type plasminogen 
activator (r-scu-PA, 
Saraplase, 
Prourokinase) 
Staphylokinase 
 
 
Plasma half-life 5 minutes; effect requires concomitant use of 
heparin and even enhanced with preliminary bolus of heparin; 
reported to have higher rate of intracranial hemorrhage; dose 20 
mg intravenous bolus. 
Plasma half-life 1-2 minutes; high fibrin selectivity; limited 
systemic plasminogen activation; associated with high incidence of 
antibody formation; dose: 10 mg intravenously over 30 min. 
 
 
 
Third-generation 
Mutant TNK-tPA 
 
 
Reduced plasma clearance with prolonged plasma half-life; can 
be administered as single intravenous bolus; 14 times more fibrin 
selective than t-PA; 80 times more resistant to PAI-1; intrinsically 
less thrombogenic and causes less platelet aggregation; dose; 
30-40 mg Intravenous bolus. 
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r-PA (Reteplase) 
 
 
Deletion mutant of t-PA; preferential binding of fibrin-bound 
plasminogen; plasma half-life 18 minutes; does not require body 
weight adjustment. 
 
n-PA (Lanoteplase) 
 
 
Plasma half-life 37 minutes; improved lytic activity relative to t-PA; 
reduced fibrin affinity. 
 
 
Vampire bat 
plasminogen activator 
 
 
Long plasma half-life, 2.8 hours; can be produced by 
recombinant technology; highly fibrin selective; can induce  
antibody formation. 
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4. ACC/AHA guidelines for administration of thrombolytic therapy to 
patients with AMI (Braunwald E et al.)9 
 
Indication 
 
Class I 
 
Class IIa 
 
Class IIb 
 
Class III 
 
Thrombolysis 
 
 
ST segment 
elevation (>0.1 mV 
in  two or more 
contiguous leads), 
time to therapy < 12 
hr, age < 75 yr. 
 
 
New onset LBBB 
(obscuring ST 
segment analysis) 
and history 
suggesting AMI 12 
hr 
 
ST segment 
elevation age 
> 75 yr 
 
 
ST segment 
elevation, 
time to 
therapy >12 
to 24 hr 
 
 
Blood 
pressure on 
presentation 
> 180 mm 
Hg systolic 
and/or 
> 110 mmHg 
 
ST segment 
elevation 
time to 
therapy 
greater than 
24 hours, 
ischemic pain 
resolved. 
 
 
ST segment 
depression 
only 
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Fibrinolytic agents used in STEMI6 
  
Initial treatment 
 
Antithrombin 
co-therapy 
 
Specific 
contra-
indications 
  
Streptokinase 
 
15 lakh units over 45-60 
minutes 
 
Heparin 
infusion for 1-2 
days 
 
 
History of 
use of 
streptokinas 
  
 
 
Alteplase 
15 mg i.v stat  
75 mg/kg in half an hour 
followed by 0.5 mg/kg in 1 
hour   
maximum dose is 100mg 
 
Heparin 
infusion for 1-2 
days 
 
 
 
Reteplase  
 
 
20 units in two doses given 
at least 10 minutes apart 
 
Heparin 
infusion for 1-2 
 
 
 
 
Tenecteplase 
(TNK-tPA) 
 
 
I.V. Bolus 
depending upon 
the body weight 
30-50 mg 
 
 
Heparin 
infusion for 1-2 
days 
 
 
55 
 
 
 
5. Contraindications and cautions for Fibrinolysis use in ST-
Elevation Myocardial Infarction10 
 
 
Absolute contraindications 
 
 ntra-cerebral hemorrhage in the past 
 
 
 AV malformation in the brain  
 
 
 Malignancies in the Brain  
 
 Ischemic CVA in the past 3 months 
 
 Suspicion of dissection of Aorta 
 
 History of bleeding disorder or active bleeding 
 
 
 History of Head injury in the past 3 months 
 
56 
 
 
 
 
Relative contraindications 
 
 
 known hypertensive patient with poor control 
 
  Systolic Blood Pressure more than 180 and Diastolic Blood Pressure more 
than 110  
 
 Ischemic CVA in the past more than 90 days 
 
 cardio-pulmonary resuscitation more than 10 minutes 
 
 history of vascular puncture at sites non-compressible 
 
 history of exposure to streptokinase in the past 
 
 Pregnancy 
 
 Peptuc Ulcer 
 
 Use of warfarin or other vitamin K antagonist  
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6. Clinical benefits of Thrombolytic Therapy in acute MI8 
 
(a) Mechanisms of benefit 
 
It is evident from both laboratory and clinical studies that the benefits of 
thrombolytic therapy in AMI are conferred exclusively by restoration of patency 
of infarct related artery. 
 
i) Magnitude of Benefit 
 
The degree of benefit that can be anticipated following successful lysis of an 
intracoronary thrombus depends on several factors including the nature of the 
end point examined, time of evaluation and the amount of myocardium that is 
salvaged ‘Salvage’ refers to the preservation of viability and contractility of 
myocardial cells that would have been irreversibly damaged in the absence of an 
intervention.  
ii) Left ventricular function benefit 
 
Since myocardial salvage is a stated goal for restoring infarct artery patency, 
measurement of infarct size would be an ideal endpoint for clinical 
reperfusion studies suggested by Braunwald E et al. Attempts to use LV 
ejection fraction as a surrogate for infarct size have not been productive because 
little difference is seen in ejection fraction between treated groups that show 
a significant difference in mortality. Alternative methods of assessing left 
ventricular function are end systolic volume or quantity echocardiography. 
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iii) Mortality Benefit 
 
First largest randomized controlled study assessing the impact of thrombolysis 
 
on mortality in patients with AMI was GISSI.11 In this study 11,806 patients 
were randomized to either IV streptokinase or standard therapy. Patients were 
enrolled upto 12 hrs after symptom onset. The overall 3 week mortality was 
lower in treated patients compared with control group. 
 
 
(b) Recent additional aspects of thrombolytic therapy12 
 
a) Inferior wall MI 
 
Old question remains unsolved, whether aggressive treatment with thrombolysis 
or angioplasty is warranted in patients with inferior MI given the potential 
economic cost and medical risks. On average, perfusion in uncomplicated 
inferior MI is good then, infarction tends to be smaller and damage may be 
distributed between the two ventricles and conduction system. 
 
 
Studies done by Grines CL et al.12 have demonstrated that mortality data 
available is 8.7% for inferior wall MI not treated with thrombolytic treatment 
6.8% mortality in inferior wall MI treated with thrombolytic treatment. 
 
Although the magnitude of benefit may not be as large for patients with 
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inferior MI as for those with anterior MI this finding relates to the overall size of 
the infarct rather than to its location. Inferior location may be consideration 
in the presence of relative contraindication. It should not by itself influence the 
decision to treatment. Clearly patients with large inferior MI as indicated by 
ECG criteria or hemodynamic instability resulting from either Right or Left 
ventricular dysfunction should be considered for aggressive therapy.  
 
b) Advanced age 
 
National guidelines have encouraged increased use of thrombolytic therapy for 
elderly patients 75 years or older,  
Study done by Christiansen CL et al.13 on 2,659 elderly patients with AMI at 
Minnesota Community hospital between 1992-1996 showed decreased mortality 
rates among those who were thrombolyzed. 
 
 
 
 
c) Late Treatment 
 
Braunwald E et al. found that no mortality benefit was demonstrated in 
LATE14 and EMERAS15 trials when thrombolytics were routinely administrated 
to patients between 12-24 hours. 
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d) Non-diagnostic ECG 
 
Patients presenting with symptom of AMI but with normal ECG did not 
demonstrate a mortality benefit from thrombolytic therapy therefore 
routine treatment of patients with normal ECG is not recommended. 
 
e) Prior Bypass surgery 
 
Remote bypass surgery should not be considered a contraindication to 
thrombolysis. Graft occlusion thrombolysis is more likely to occur than natural 
vessel thrombosis which is relatively resistant to thrombolysis due to large 
thrombus mass and poor flow through the graft resulting in limited delivering of 
lytic agents.  
 
 
 
 
 
f) Lytic regimen 
 
Increasing the IV dose of streptokinase 15 lakh unit does not appear to 
increase efficacy, some studies have shown that streptokinase in dose of 7.5 lakhs 
is as effective as 1.5 million unit. This dose was arrived empirically although short 
term weight adjusted high dose rt-PA has been investigated and appears to 
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improve early patency rates there is a general reluctance to employ an increased 
dose in an average sized patient in view of the excess intracranial bleeding that 
was observed in patients receiving rt-PA 150 mg over 6 hours in the TIMI trial 
held by William JL et al.16 
 
 
 
ADJUNCTIVE ANGIOPLASTY 
 
Emergency cardiac catheterization of patients receiving thrombolytic therapy with 
subsequent angioplasty has been evaluated in several studies like Hogg KJ et 
al.17 Dilatation of vessels in which patency has been restored by thrombolysis has 
no proven benefit and may infact be detrimental. In addition, reocclusion rates are 
not decreased and complication rates are relatively high. Rescue or salvage 
angioplasty of vessels that remain occluded following thrombolytic therapy may 
have a clinical role. Although success rates are relatively low and, reocclusion 
rates are relatively high in this selected group of patients, prognosis may be 
improved with successful restoration of patency. 
 
 
7) Complications 
 
(a) Bleeding  
The Aim of thrombolysis is to lyse the thrombus in the artery and establish blood 
flow, since this process involves activation of the plasminogen and the expected 
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complication is bleeding. A thrombus which is preventing a vascular leak in a blood 
vessel is also lysed and leads to bleeding 
 
 
Bleeding can occur in various places and is usually classified as either 
 
(i) Intracranial or 
 
(ii) Systemic 
 
 
(i) Intracranial 
 
Recent studies signify the incidence and risk factor for intracranial 
hemorrhage. The risk is around 0.3 - 0.5 %.  These complications are rarely 
diagnosed because a massive infarct or haemorrhage may cause sudden death 
before imaging studies could be done and the death is usually attributed to cardiac 
cause.  
 
In ISIS-318 trial 0.4% without heparin, 0.6% with heparin the risk of ICH is more 
with the heparin used group than the other . However there was decreased risk of 
thrombotic stroke when heparin was used. 
 
 
IV heparin use in STEMI has increased the  risk for intracranial hemorrhage but 
the risk of a ischemic stroke is less. 
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(ii) Systemic bleeding 
 
The thrombolyzed Patient is at a high risk for any invasive procedures and also for 
coronary Angiogram or PTCA. 
 
(B) Immunologic complications 
 
Active compound of streptokinase is produced by beta hemolytic 
streptococcus;  since it is a common pathogen it leads to frequent allergic reactions.   
These allergic manifestations are acute and delayed. Delayed is characterised 
by fever, arthralgia, leucocytoclastic vasculitis, renal failure, interstitial 
pulmonary abnormalities. 
 
 
(C) Hypotension 
 
Hypotension occurs in MI due to failure of ventricles to pump blood, inadequate 
filling of ventricles etc. Hypotension may occur following thrombolysis due to 
massive release of vasodilatory chemokines like HMWK and bradykinin.  
In a trial it was established that fall of 35 mmHg in systolic BP in patients treated 
with streptokinase and that 38% had systolic BP <90 mmHg transiently. 
Hypotension documented in GISSI-211 trial 4.4% with streptokinase. In ISIS-318 
trial 6.8% with streptokinase. 
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 The fall in Blood pressure which occurs in patients treated with streptokinase is 
due to allergic reaction and it responds well to I.V. Fluids and anti allergic 
medication and other supportive measures 
 
(D) Myocardial rupture of reperfusion injury 
 
Myocardial reperfusion may lead to release of chemokines from dying cells and 
leads to further inflammation and also occlusion of micro-circulation by the 
inflammatory cells.  
 
 
A study conducted by Essen R et al.19 showed late thrombolysis may cause 
reperfusion injury and even cause myocardial rupture leading to death. 
 
 
This Myocardial rupture was more in patients’ thrombolyzed after 12 hours of 
symptom onset and occurs due to the dissection of the free wall of ventricle which 
is infarcted.  
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(E) Thromboembolic Complications 
 
 Patients with longstanding valvular heart disease may have a clot in the chambers 
of the heart and this may be partially lysed and may be embolised to the systemic 
circulation leading to fatal complications.  
 
 
 
8. Assessment of Myocardial Reperfusion 
 
Coronary artery patency and myocardial reperfusion can be assessed soon after 
completion of administration of thrombolytic therapy and also following discharge 
of such a patient from the hospital. Hence it can be assessed in two stages. 
 
a) Early assessment 
 
b) Late assessment 
 
 
Early assessment 
i) Relief of pain 
Earliest symptom of reperfusion is the prompt relief of chest pain followed by a 
sense of well being. 
 
ii) Resolution of ST segment deviation: 
 
Successful reperfusion is usually followed by rapid return of ST segment 
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towards the base line. Brockrmeirer J et al.20 reported a reduction in ST segment 
elevation to 50% of pre-treatment value within one hour of myocardial 
reperfusion. In contrast ST segment elevation persisted for a longer time in 
patients with no reperfusion. 
 
 
 
iii) Cardiac enzymes 
 
Following reperfusion when antegrade coronary flow is re-established an 
abrupt and marked acceleration of CK wash out results in steep rise in serum 
CK activity. A peak CK level is usually reached in 10-14 hours in patients 
with early reperfusion following thrombolytic therapy in contrast to 20-25 
hours in those patients with conventional treatment. 
 
 
To obtain CK-MB time activity curve, blood must be collected for 
determination of CK-MB at 15-30 minutes interval for the initial 2-4 hours and 
hourly thereafter for the first 24 hours. 
 
Another enzyme which is very indicative of reperfusion is Myoglobin, which 
peaks even earlier than CK. Estimation of time activity curve of both these 
enzymes can be used to estimate the time of recanalisation of occluded artery. 
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iv) Reperfusion Arrhythmias 
 
Various forms of ventricular arrhythmias have been described as a sign of 
myocardial reperfusion. Ventricular ectopic beat occurring late in diastole, 
ventricular bigeminy or trigeminy and occasional fusion beats have all been 
seen. However almost 50% of the patients exhibit accelerated idioventricular 
rhythm (AIVR) following reperfusion. 
 
These reperfusion arrhythmias are probably due to increase in automaticity and 
usually do not require any treatment. Ventricular tachycardia and ventricular 
fibrillation which by and large are very rare, require prompt treatment. 
 
AV block and intraventricular conduction defect often occur with 
reperfusion, complete AV block complicating anterior myocardial infarction, on 
reverting to sinus rhythm after thrombolysis, is accompanied by bradycardia and 
hypotension which responds well to atropine. 
 
 
v) Echocardiographic Evaluation 
 
Determination of changes in the regional rather than global ventricular 
function is now recognized as the proper way to study patients before and 
after reperfusion. Most studies have shown an improvement in the regional 
function of the perfused area. Data from 125 patients in the Registry of 
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European Society of Cardiology indicate an increase in ejection fraction in most 
patients when treatment was initiated before three hours after the onset of chest 
pain. 
 
 
Chia BI, YID et al.21 reported global LV function improvement in patients with 
early reperfusion. An increase in EF from 50% from 0 hour to 61% at the end of 7 
days was observed. No such changes were seen in patients treated conventionally. 
 
 
 
OTHER WAYS OF ASSESSMENT OF MYOCARDIAL SALVAGE 
 
High dose, short-term early IV STK results in early myocardial reperfusion 
associated with significant improvement in ventricular function. This has 
been confirmed by the following studies. 
 
1) Contrast ventriculography: Analysing LV regional wall motion and 
measuring percentage systolic shortening. 
 
 
2) Thallium 201 perfusion scan showing about 40% reduction in the size of 
the perfusion defect. 
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3) Combined Thallium 201 and Technetium 99m Pyrophosphate scintigraphy 
have been used by Ohsuzu F et al.22 to assess myocardial salvage. 
 
 
4) ECG Indices: 
 
a) Gradual increase in the R wave amplitude. 
 
b) Decrease in Q wave during the days following infarction. 
 
 
5) Positron emission tomography (PET Scan): Showing recovery of 
aerobic metabolism of ventricular myocardium following myocardial reperfusion. 
 
 
6) Newer imaging techniques like X-ray computed tomography, Thallium 201 
single photon emission computed tomography and MRI – all provide a measure 
of the extent of myocardial necrosis 
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Late assessment14 
 
 
1) Treadmill stress test (TMT): TMT using modified Bruce protocol at six 
weeks revealed an ischemic response in 18% of STK treated patients, while in the 
control group TMT was positive in 42% of cases. 
 
2) Angiographic evaluation of patency is the fool-proof method of assessing 
the success or failure of therapy. Earliest sign of reperfusion is the establishment 
of a sluggish flow of contrast through the vessel. As thrombolysis continues the 
lumen and the coronary flow generally increase and ultimately this lumen will 
remain open. However during therapy a cyclic pattern of reperfusion and re-
occlusion may occur before substantial reperfusion is achieved. Neither 
Nitroglycerine nor Calcium channel blockers have been effective in avoiding 
the intermittency of occlusion. 
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9. Conjunctive Treatment 
 
Thrombin Antagonists and  Antiplatelet Agents 
 
Two major limiting factors for the clinical benefits of thrombolytic therapy are: 
 
1. One fourth to one fifth of the thrombus in coronaries are not thrombolysed 
 
2. One in 10 patients develop re-occlusion of the thrombolyzed vessel 
 
 
These caused by increased clotting activity at the site of occlusion where the 
atherosclerotic plaque is present. Thrombin, the main enzyme in the clotting 
pathway stimulates the fibrin and causes platelet activation and the thrombus is 
formed. These pro-coagulant cells are activated further by the clotting factors and 
this leads to vicious cycle leading to thrombus formation and occlusion of the 
vessel.  
 
The treatment plan involves activating fibrinolysis and inhibit clotting pathway 
and inhibiting the factors that favour clotting. 
 
Heparin and platelet inhibitors are the main drugs used to inhibit clotting and 
inhibit platelet aggregation and prevent clot formation. But these drugs may cause 
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bleeding when used in conjunction with fibrinolysis. Hence highly selective drugs 
with less complication are needed to prevent resistance to fibrinolysis and re-
occlusion. 
 
 
This is the rationale behind use of antiplatelet drugs in acute STEMI along with 
fibrinolytic therapy, these drugs inhibit platelet plug formation and also act on the 
atherosclerotic plaque and stabilises it, and these drugs however in some cases may 
cause bleeding leading to fatal complication like intra-cerebral haemorrhage. 
 
 
Combination Therapy 
 
The mechanism of formation of thrombus in a coronary artery clearly justifies the 
use of combination therapy i.e. anticoagulant and anti-platelet drugs along with 
fibrinolysis. 
 
 
The commonly used combination is heparin, aspirin with fibrinolysis shows a 
benefit and increased efficacy of thrombolysis and prevents re-occlusion of a 
thrombolysed vessel. Besides the benefit, these drugs cause an increase in the 
hemorrhagic complications especially when the patient is planned for an invasive 
procedure like angiogram or PTCA, there are several trials demonstrating both the 
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beneficial effects of this combination of heparin, aspirin and fibrinolytics and the 
increased risk of bleeding associated with combination, in GISSI-2 study the 
hemorrhagic complications are more with the use of streptokinase compared with 
other fibrinolytic drugs.    
 
 
 
ELECTROCARDIOGRAPHY23 
 
Myocardial infarction (MI) is reflected electrocardiographically by the 
electrocardiographic parameters of ischemia, injury and necrosis, are reflected 
by T wave changes, ST-segment displacement and the appearance of Q 
waves, respectively. 
 
 
LOCALIZATION OF INFARCTION23 
 
ECG localization of myocardial infarction other than differentiation of anterior 
from inferior and posterior is at best an approximation of its true anatomical 
location. 
 
 
Accuracy is affected, for example by the distance of the electrode from the 
heart a common variable. 
 
Using the Q-wave as a marker of infarction, one can identify an infarct a 
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SEPTAL when a Q-wave is present in leads V1 and V2, ANTERIOR when it 
is present in leads V3 and V4, ANTEROSEPTAL it present in V1 to V4, 
LATERAL when present in leads I, aVL and V6. ANTEROLATERAL when 
present in leads I, aVL and V1 to V6, HIGH LATERAL when present in leads I 
and aVL, INFERIOR when present in leads II, III and aVF, 
ANTEROINFERIOR TRANSSEPTAL or  APICAL when present in leads II, III 
and aVF and in one or more of leads V1 to V4.  
 
 
A POSTERIOR infarct is recognized by a prominent R-wave in V1 or V2 and 
a POSTEROLATERAL infarct by Q-wave in leads I and aVL and a prominent R-
wave in lead V1 or V2. 
 
 
A RIGHT VENTRICULAR INFARCTION (RVI) can be diagnosed by taking 
Right sided chest leads i.e., V3R, V4R, V5R and V6R more specific being V4R. ST-
segment elevation of more than or equal to 0.1 mv (1 mm) in atleast one of the 
right precordial leads stated above, more specific in V4R is considered an 
evidence of RVI in patients with acute inferior myocardial infarction. QS-
complexes in V4R and V3R along with ST-segment elevation, is almost 100% 
specific diagnostic of RVI in acute myocardial infarction. These changes 
usually disappears within 10-18 hours after the onset of chest pain in 50% of 
patients (a transient phenomenon). 
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ST SEGMENT ELEVATION 
 
 
(1) Molecular Basis of Electrocardiographic ST-Segment Elevation 
 
Elevation of the ST segment in the electrocardiogram (ECG) is a classical 
hallmark of acute transmural myocardial ischemia. Indeed, ST elevation is the 
major clinical criterion for deciding which patients with chest pain require 
emergent coronary revascularization. 
 
 
In 1909 Eppinger and Rotenberg24 observed ST segment elevations in dogs with 
experimental ventricular injury, and in 1920 Pardee25 published his description of 
ST segment elevation as a clinical sign of coronary obstruction. More than 80 years 
have passed since these observations, yet the exact mechanism is still a subject 
of debate. 
 
 
Myocardial cells during the early phase of repolarization carry the same 
transmembrane potential. Therefore they will not have any net current flow at 
the time the ST segment is inscribed. ST segment elevation from myocardial 
ischemia is caused by abnormal current flow (current of injury) between the 
boundary of normal and ischemic zones. 
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Various studies have suggested that activation of sarcolemmal ATP-sensitive 
potassium (KATP) channels by ischemic ATP depletion may play a role, but 
little direct evidence is available. 
 
 
Li et al.26 studied mice with homozygous knockout of the Kir 6.2 gene, which 
encodes the pore-forming unit of cardiac KATP channels. In the presence of 
left anterior descending artery ligation, while the ST segment elevation was 
evident in normal mice the elevation was absent in those with the knockout, 
supporting the concept that the KATP channels are responsible for ST segment 
elevation. 
 
Mechanistically, ischemia leads to an increase of extracellular K1 with 
membrane depolarization, depletion of intracellular ATP, and action 
potential shortening. Together, these cellular events lead to electrical 
inhomogeneity within the heart, generating injury currents between ischemic and 
normal cells and shifting the ST segment in the ECG. 
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(2) ST Segment Elevation Resolution after Thrombolytic Therapy 
 
 
The ST segment was measured 80 ms after the J point. The summed ST 
segment elevation was measured by summing the ST amplitude in all leads with 
ST elevation at baseline (before fibrinolysis) and at 90 minutes (postfibrinolysis), 
using methods described by Schroder and colleagues.27 
 
 
The per cent resolution of STR was calculated as the initial sum of ST segment 
elevation minus the sum of ST segment elevation on the second ECG, divided by 
the initial sum of ST segment elevation. 
 
Three categories of resolution have been proposed and validated prospectives: 
 
Category 1: < 30%, resolution of the sum of ST-segment elevation 
 
Category 2: > 30 but < 70%, resolution of the sum of ST-segment elevation 
 
Category 3: > 70% resolution of the sum of ST-segment elevation 
 
 
These three categories were shown to be prognostically important at 3 hours 
after the initiation of thrombolytic therapy. 
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(3) Prognostic importance of ST segment resolution after thrombolysis in 
acute myocardial infarction 
 
 
Resolution of ST segment elevation has been shown to be a simple and useful 
predictor of final infarct size, left ventricular function, and clinical outcome after 
both thrombolytic and interventional approaches to the management of acute 
myocardial infarction. 
 
 
The primary goal of reperfusion therapy has shifted from opening of the 
infarct related artery to establishment of myocardial tissue perfusion.It has 
been reported that STR is a practical and useful measure of this latter variable. 
 
The gold standard test for the success or failure of thrombolytic therapy is 
considered to be coronary angiography. 
 
However, such an examination represents a “snapshot” of the coronary 
epicardial tree at a given moment, and cannot describe the dynamic changes that 
take place over time in the infarct-related artery and the myocardium supplied 
by the artery. 
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A number of studies compared the prognostic value of STR with coronary 
angiography results after thrombolytic therapy. 
 
 
De Lemos et al.28 observed that patients with complete(>70%) STR from 
baseline at 90 minutes had a 94% probability of IRA patency (TIMI-2 or 3), a 
TIMI-3 flow rate of 79%, and 30 day cardiac mortality as low as 1%. 
 
 
Patients with partial (30±70%) STR had 72% patent IRA and a TIMI-3 flow 
rate of 50%. Thirty day mortality in this group was 4.2%. 
 
 
 
Cases with no (<30%) STR presented with 68% patent IRA and 44% TIMI-3 flow 
rate, while the 30 day mortality was 5.9%. 
 
 
Other studies, such as GISSI,11 found that two-thirds of the patients had 
complete (>50%) STR 4 hours after thrombolysis, and 30 day cardiac mortality of 
3.5% versus 5.7% in those without resolution. 
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Schroder et al.27 studied the prognostic power of early STR 3 hours after the start 
of thrombolysis in patients recruited in the Intravenous Streptokinase in 
Myocardial Infarction Study. 
 
Complete (>70%) resolution was observed in 45%, partial resolution (70 ± 
30%) in 31% and no resolution in 24%. 
 
For the three groups, infarct size (measured by CK-MB percent release), 
echocardiographic left ventricular ejection fraction 1 month after the event, 
and mortality rates at 21 days (2.2%, 3.4%, and 8.6%) were assessed. 
 
The authors concluded that no STR was the most powerful independent 
predictor of early mortality. 
Neuhaus KL et al.29 found in the study that simple measurements of ST 
segment deviation existing in the one ECG lead with greatest deviation on 
ECG 90/180 min after thrombolysis enables the identification of the major 
subsets of patients who are either at very low or exceptionally high risk of 
mortality. 
 
Schroder K et al.30     found that persistent ST elevation may be due to  
microvascular damage impeding myocardial blood supply. 
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Poor recovery of left ventricular function after ischemic myocardial injury may 
cause increase in mortality. Sum of ST segment resolution may be used for 
assessing infarct size, left ventricular function,  epicardial vessel patency and 
mortality 
 
It is worth mentioning here the results of research in which STR was studied 
after primary percutaneous transluminal coronary angioplasty. 
 
 
In the Zwolle Angioplasty Study,31 all patients attained patent IRA with TIMI-3 
flow, yet complete (>70%) STR was seen in 51% patients, partial (30±70%) in 
34%, and 15% had no (<30%) STR. 
 
 
Matetzky et al.32     examined the STR of 117 patients after successful 
(TIMI-3 flow) angioplastic reperfusion for acute myocardial infarction. Seventy-
six percent of the patients had complete (>50%) STR while 24% did not. 
 
 
The group of patients without STR was associated with high in-hospital 
(11% vs. 2%) and long-term mortality (21% vs. 12%), as well as with worse 
pre-discharge and late left ventricular ejection fraction. 
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Such results support the theory that myocardial reperfusion requires patent IRA 
and an intact microvascular bed, and that STR is a marker of myocardial 
reperfusion and not just of coronary artery patency. 
 
 
Several investigators recently reported that persistent ST segment elevation is 
predictive of poor ventricular recovery and mortality. Andrews and co-
workers demonstrated that patients with complete (>50%) STR and TIMI-2 
or 3 on angiography presented with improved wall motion 48 hours after 
thrombolytic therapy, while those without STR had worse wall motion. 
 
 
Van’t Hof,3 Somitsu33 and Santoro34 and their teams reached comparable 
conclusions, and the hypothesis was supported by results from 
contrast echocardiography35 and nuclear scintigraphy.36 
 
 
The large majority of studies defined success or failure of thrombolysis based on 
ST deviation analysis at 90 minutes from the start of therapy. 
 
The main principle was to reserve sufficient time for an invasive intervention if 
fibrinolysis was unsuccessful, in order to generate reflow to the jeopardized 
myocardium 
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In the HIT-4 substudy37 mentioned earlier, Schroder et al. compared the 
prognostic value of STR at 90 and 180 minutes after the start of thrombolytic 
therapy. 
 
 
Complete STR at 180 minutes identified 50% of the patients with a 30 day 
cardiac mortality less than 2% and was the most powerful independent predictor 
of early cardiac mortality in multivariate analysis. 
 
 
 
While mortality rates doubled at 180 minutes, the proportion of patients with no 
STR decreased by two-thirds from 90 to 180 minutes. 
 
 
Those observations are consistent with recanalization of IRA later than 90 
minutes after the start of streptokinase therapy. 
 
 
In contrast, de Lemos et al.28 reported that patients with complete, versus those 
without STR at 60 minutes are likely to present with even lower risk for mortality 
and congestive heart failure. 
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Nonetheless, such an early analysis will facilitate a more rapid decision about 
rescue PTCA,   
 
Been M et al. found that rapid reduction of ST elevation will be predicted 
by relief from chest pain, early peaking of serum concentration of  CK, 
reperfusion arrhythmia. 
 
 
 
Another point of controversy between two aspects of STR is continuous versus 
“snapshot” ST segment monitoring. 
 
 
Shah et al demonstrated that a rapid and stable STR pattern was an 
independent predictor for combined mortality or congestive heart failure. 
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METHODOLOGY 
 
SOURCE OF DATA 
 
All patients with diagnosis of acute ST segment elevation according to 
ACC/AHA guidelines 1999,10 admitted to Thanjavur Medical college during 
period from “ December 2013 to August 2014”. 
 
METHOD OF COLLECTION OF DATA 
Sample size: Minimum of 60 cases of diagnosed ST segment elevation 
myocardial infarction. 
 
Sampling method: Simple random sampling 
 
INCLUSION CRITERIA 
All the patients with first attack of ST segment elevation myocardial infarction 
diagnosed according to ACC/AHA guidelines 199910     without any 
conventional contraindications for thrombolysis before 12 hours of onset of 
symptoms. 
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EXCLUSION CRITERIA 
 Patients with previous history of acute myocardial infarction patients 
coming to hospital after 12 hours of onset of symptoms. 
 
 Patients with conventional contraindications for thrombolytic therapy. 
 
 Patients with previous history of valvular heart disease, cardiomyopathies 
and congenital heart disease. 
 
 If patient dies before 90 minutes after thrombolytic therapy 
 
 Bundle branch block 
 
Data will be collected in a pre-tested proforma by meeting objectives of study, 
detailed history, physical examination; thorough cardiovascular and other 
systems examination and necessary investigations are recorded. 
 
A 16 lead ECG consisting of 12 conventional leads and 4 right sided chest 
leads was recorded at the time of admission, 90 minutes after the 
thrombolysis everyday subsequently for 7 days. Standard lead II was cased to 
monitor and record rhythm disturbances.  
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ECG’s were recorded on “Bionet Cardio Care 2000 Machine” with 3 channel 
and 1 rhythm and other standard settings 1mV = 10mm and 25mm/sec 
Patients monitored on Philips Heart Start XL cardiac monitor cum Biphasic 
Defibrillator 
 
The other routine investigations to which patients were subjected are as follows: 
Hb% 
TC 
DC 
ESR 
Urine:  Albumin 
     Sugar 
     Microscopy 
Lipid profile within 24 hours of onset of chest pain 
FBS, PPBS whenever necessary 
B. urea 
S creatinine 
S. electrolytes 
 
 
88 
 
CKMB 
Trop T 
Chest X-ray PA view (whenever necessary) 
 
ST segment was measured 80 millisec after the J point. The summed ST 
segment elevation was measured by summing the ST segment amplitude in all 
leads.  
With ST elevation at base line ECG (before thrombolysis) and at 90 min 
ECG (post thrombolysis) using methods described by Schroder et al.27 
 
The percent resolution of ST segment resolution was calculated as the sum of ST 
segment elevation on first ECG minus the sum of ST segment elevation on second  
ECG, decided by initial sum of ST segment elevation. 
 
Based on values obtained, study population divided into three categories: 
A, B and C. 
A. Category A: < 30% resolution of the sum of ST segment elevation. 
 
B. Category B: 30% - 70% resolution of the sum of ST segment elevation. 
 
C. Category C: > 70% resolution of the sum of ST segment elevation. 
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Clinical details were recorded prospectively. In hospital, major adverse events 
were defined as the occurrence of any of the following. Killip Class II–IV, 
Left ventricular failure, cardiogenic shock, recurrent angina, significant 
arrhythmias (which needs definite pharmacological, DC cardioversion and 
interventions like pacing) and death.  
 
Adverse events were divided according to timing < 48 hours after admission and 
> 48 hours after admission. An uncomplicated course was defined as no major 
adverse event during entire inpatient stay. 
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Table 3b : Symptoms at presentation 
 
Symptoms 
 
Number of cases Percentage p-value 
 
Chest pain 57 95 0.0000 
Sweating  52 86 0.0000 
Breathlessness 15 25 0.0000 
Palpitation  3 5 0.0000 
Syncope  6 10 0.0000 
 
 
In this study chest pain was the most common mode of presentation, present in 57 
patients associated with sweating in 52 patients, breathlessness seen in 15 patients. 
Syncope was seen in 6 patients and palpitation in 3 patients. 
Figure 6: Symptoms at presentation 
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Table 4: Risk factors 
 
 
 
Risk factors 
 
 
Number of cases 
 
 
Percentage 
 
 
p-value 
  
Smoking 
 
 
45 
 
 
75 
 
 
0.000 
  
Hypertension 
 
 
31 
 
 
51.7 
 
 
0.796 
  
Diabetes mellitus 
 
 
21 
 
 
35 
 
 
0.020 
  
Past history of 
angina 
 
 
 
10 
 
 
 
16 
 
 
 
0.000 
 
 
Family history of 
IHD 
 
 
 
5 
 
 
 
8 
 
 
 
0.000 
 
 
Figure 7: Risk factors 
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Figure 13: Killip Class
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Figure 17: Outcome 
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Inhospital mortality 
 
 
Categories 
 
 
A B C 
 
 
No. % No. % No. % 
 
 
6 66.7% 0 0 1 4% 
 
 
p=0.000 p=0.014 p=0.118 
 
 
Cause of death 
 
 
Number Percentage 
 
 
Cardiogenic shock 5 71.4% 
 
 
VT / VF 2 28.6% 
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DISCUSSION 
 
 
 
 
The present study documents the usefulness of the standard electro- 
cardiographic ST segment resolution after 90 min following thrombolytic therapy 
as a predictor of coronary artery reperfusion. 
 
 
Table 8: Age incidence among different studies 
 
 
 
Studies 
 
 
Number of cases 
 
 
Year 
 
 
Mean age 
  
Schroder et al.27 
 
 
1398 
 
 
1995 
 
 
60.9 12 
 
 
French et al.39 
 
 
869 
 
 
2001 
 
 
55.5 9.7 
 
 
Zeymer U et al.40 
 
 
761 
 
 
2001 
 
 
60.9 11 
 
 
Dong et al.41 
 
 
121 
 
 
2002 
 
 
60 11 
 
 
Bhatial et al.42 
 
 
85 
 
 
2004 
 
 
62.7 12 
 
 
Sezer, Nasanci, 
Umman et al.43 
 
 
 
33 
 
 
 
2004 
 
 
 
58.2 11.2 
 
 
Present study 
 
 
60 
 
 
2014 
 
 
50.7 9.6 
 
 
 
 
In present study the mean age of patient is 50.7 years compared to other studies in 
present study mean age of population is 10 years younger. 
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Table 9: Sex incidence among different studies 
 
 
 
 
Authors 
 
 
Number of 
cases 
 
 
 
Year 
 
 
 
Male (%) 
 
 
 
Female (%) 
 
 
Schroder et al.27 
 
 
1398 
 
 
1995 
 
 
76% 
 
 
24% 
  
French et al.39 
 
 
869 
 
 
2001 
 
 
80% 
 
 
20% 
  
Zeymer U et al.40 
 
 
761 
 
 
2001 
 
 
76.71% 
 
 
23.3% 
  
Dong et al.41 
 
 
121 
 
 
2002 
 
 
80% 
 
 
20% 
  
Bhatial et al.42 
 
 
85 
 
 
2004 
 
 
69% 
 
 
31% 
  
Sezer, Nasanci, 
Umman et al.43 
 
 
 
33 
 
 
 
2004 
 
 
 
70% 
 
 
 
30% 
 
 
Present study 
 
 
60 
 
 
2014 
 
 
80% 
 
 
20% 
 
 
 
 
In the present study, there is a male preponderance. There is similar male 
preponderance in different study groups. 
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Table 10: Risk factors among different studies 
 
 
 
 
 
 
Risk factors 
 
 
 
French 
et al.39 
(2001) 
(N = 869) 
 
 
 
Zeymer U 
et al.40 
(2001) (N = 
761) 
 
 
 
Dong 
et al.41 
(2002) 
(N = 121) 
 
 
 
Bhatial 
et al.42 
(2004) 
(N = 85) 
 
 
 
Present 
study 
(2014) 
(N = 60) 
 
 
Smoking 
 
 
43% 
 
 
45.5% 
 
 
48% 
 
 
39.5% 
 
 
75% 
  
Hypertension 
 
 
27% 
 
 
37.8% 
 
 
63% 
 
 
45.5% 
 
 
51% 
  
Diabetes 
 
 
9% 
 
 
13.1% 
 
 
20% 
 
 
24% 
 
 
35% 
  
Prior angina 
 
 
23% 
 
 
- 
 
 
- 
 
 
25% 
 
 
16% 
 
 
 
 
In present study smoking is single most common risk factor, followed by 
hypertension and diabetes. Percentages of smokers are high compared to other 
studies. Percentage of diabetes high also when compare to other studies. 
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Table 11: Baseline variable among ST resolution sub groups 
(Complete resolution group: > 70% resolution) 
  
 
Schroder 
et al.,27 1995 
(n=1398) 
 
 
French 
et0al.,39 
2001 
(n=869) 
 
 
Dong 
et0al.,40 
2002 
(n=121) 
 
 
Anderson 
et al.,44 
2002 
(n=2352) 
 
 
Present 
study, 
2014 
(n=60) 
 
 
Percentage of 
cases 
 
 
 
49% 
 
 
 
38.25% 
 
 
 
38.11% 
 
 
 
44% 
 
 
 
41.7% 
 
 
Mean age 
 
 
60.9 
 
 
57.8 
 
 
60 
 
 
63 
 
 
53.0010 
 
 
Female 
 
 
24% 
 
 
20% 
 
 
22% 
 
 
30% 
 
 
20% 
 
 
Smoking 
 
 
42% 
 
 
44% 
 
 
48% 
 
 
42% 
 
 
80% 
 
 
Hypertension 
 
 
30% 
 
 
27% 
 
 
53% 
 
 
39% 
 
 
36% 
 
 
Diabetes 
 
 
10% 
 
 
8% 
 
 
12% 
 
 
13% 
 
 
16% 
 
 
Anterior wall 
 
 
33% 
 
 
- 
 
 
20% 
 
 
39% 
 
 
52% 
 
 
Inferior wall 
 
 
77% 
 
 
- 
 
 
80% 
 
 
61% 
 
 
48% 
 
 
Mean time of 
onset of 
symptoms to 
initiation of 
treatment (hours) 
 
 
 
 
 
- 
 
 
 
 
 
2.8 1.1 
 
 
 
 
 
3.7 2 
 
 
 
 
 
2.9 
 
 
 
 
 
2.810.95 
 
 
Killip class > I 
 
 
10% 
 
 
- 
 
 
8% 
 
 
- 
 
 
20% 
 
 
 
Base line variables in complete resolution group similar to other study groups, 
except for age and smoking. Patients in the present study are 10 years 
younger compared to other study groups. Percentage of smokers among 
population group of present study almost doubles that of other study groups. 
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Table 12: Baseline variable among ST resolution sub groups (Partial resolution 
group 30 – 70%) 
 
  
Schroder 
et al.,27 
1995 
(n=1398) 
 
 
French 
et0al.,39 
2001 
(n=869) 
 
 
Dong 
et0al.,40 
2002 
(n=121) 
 
 
Anderson 
et al.,44 
2002 
(n=2352) 
 
 
Present 
study, 
2014 
(n=60) 
 
 
Percentage of cases 
 
 
30% 
 
 
31% 
 
 
35.87% 
 
 
29% 
 
 
43.3% 
 
 
Mean age 
 
 
61.6 
 
 
56.9 9.6 
 
 
61 14 
 
 
62 
 
 
52.48.7 
 
 
Female 
 
 
26% 
 
 
23% 
 
 
20% 
 
 
22% 
 
 
23% 
 
 
Smoking 
 
 
- 
 
 
41% 
 
 
49% 
 
 
44% 
 
 
69.2% 
 
 
Hypertension 
 
 
- 
 
 
26% 
 
 
52% 
 
 
40% 
 
 
53.8% 
 
 
Diabetes 
 
 
16% 
 
 
8% 
 
 
22% 
 
 
13% 
 
 
34.6% 
 
 
Anterior wall 
 
 
62% 
 
 
- 
 
 
47% 
 
 
56% 
 
 
53.8% 
 
 
Inferior wall 
 
 
38% 
 
 
- 
 
 
53% 
 
 
44% 
 
 
46.2% 
 
 
Time of treatment 
(hours) 
 
 
 
- 
 
 
 
2.8 1.3 
 
 
 
4.4 2.8 
 
 
 
2.9 
 
 
 
5.01.22 
 
 
Killip class > I 
 
 
14% 
 
 
- 
 
 
7% 
 
 
- 
 
 
30.7% 
 
 
 
Majority of baseline variables in partial resolution group similar with different 
study groups. But mean age of present population group is at least 10 years 
younger compared to other studies. Percentage of smokers and diabetes are 
more in present population group when compared to other study groups. 
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Table 13: Baseline variable among ST resolution sub groups (No of 
resolution group < 30%) 
 
  
Schroder 
et al.,27 
1995 
(n=1398) 
 
 
French 
et0al.,39 
2001 
(n=869) 
 
 
Dong 
et0al.,40 
2002 
(n=121) 
 
 
Anderson 
et al.,44 
2002 
(n=2352) 
 
 
Present 
study, 
2014 
(n=60) 
 
 
Percentage of cases 
 
 
21% 
 
 
30.6% 
 
 
34.97% 
 
 
26% 
 
 
15% 
 
 
 
Mean age 
 
 
 
62.8 
 
 
58.3 
9.2 
 
 
 
60 
 
 
 
63 
 
 
 
50.7710.2 
 
 
Female 
 
 
27% 
 
 
20% 
 
 
17% 
 
 
25% 
 
 
22.22% 
  
Smoking 
 
 
- 
 
 
43% 
 
 
40% 
 
 
41% 
 
 
77.8% 
  
Hypertension 
 
 
- 
 
 
27% 
 
 
63% 
 
 
44% 
 
 
66.7% 
  
Diabetes 
 
 
22% 
 
 
11% 
 
 
19% 
 
 
16% 
 
 
88.9% 
  
Anterior wall 
 
 
58% 
 
 
- 
 
 
62% 
 
 
56% 
 
 
88% 
  
Inferior wall 
 
 
42% 
 
 
- 
 
 
38% 
 
 
44% 
 
 
12% 
  
Time of treatment 
(hours) 
 
 
 
- 
 
 
 
2.8 1.1 
 
 
 
4.5 2.8 
 
 
 
2.8 
 
 
 
5.22.00 
 
 
Killip class > I 
 
 
34% 
 
 
- 
 
 
26% 
 
 
- 
 
 
77.77% 
 
 
 
 
When compared to other study groups.. Diabetes is most frequent risk factor 
followed by smoking and  hypertension. Percentage of risk factors are high when 
compare to other study groups. Ratio of anterior wall myocardial infarction to 
inferior wall MI very high when compared to other study groups. Mean time 
of onset of symptoms to treatment also high in present study compared to other 
study groups. 
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Table 14: Adverse events in such groups (complete resolution 
group) and inhospital mortality 
 
  
Schroder et al.,27 
1999 (n=1398) 
 
 
Anderson et al.,44 
2002 (n=2352) 
 
 
Present study, 
2014 (n=-60) 
 
 
LVF 
 
 
13% 
 
 
13.9% 
 
 
12% 
 
 
Cardiogenic shock 
 
 
2.6% 
 
 
2.2% 
 
 
0 
 
 
Arrhythmias 
 
 
13% 
 
 
NA 
 
 
16% 
 
 
Recurrent angina 
 
 
13% 
 
 
3.4% 
 
 
0 
 
 
Inhospital mortality 
 
 
4% 
 
 
3.2% 
 
 
4% 
 
 
 
 
Adverse events in complete resolution group in the present study are similar to 
other study groups. Arrhythmias are most frequent adverse events. In the 
present study group which can be comparable to other study groups. 
followed by left  ventricular failure. In hospital mortality is 4% in present study 
which is similar to other study groups. 
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Table 15: Adverse events in such groups (partial resolution 
group) and inhospital mortality 
 
 
 
 
Partial resolution 
group 
 
 
Schroder 
et al.,27 1995 
(n=1398) 
 
 
 
Anderson et al.,44 
2002 (n=2352) 
 
 
 
Present study, 
2014 (n=60) 
 
 
LVF 
 
 
20% 
 
 
18.9% 
 
 
38.5% 
 
 
Cardiogenic shock 
 
 
3.8% 
 
 
3.1% 
 
 
0 
 
 
Arrhythmias 
 
 
15% 
 
 
NA 
 
 
30.8% 
 
 
Recurrent angina 
 
 
183% 
 
 
2.7% 
 
 
30.8% 
 
 
Inhospital mortality 
 
 
2% 
 
 
6.6% 
 
 
0 
 
 
 
 
Most common adverse event in partial resolution group in the present study is left 
ventricular failure followed by arrhythmias and recurrent angina, which is  
comparable to other study groups. However percentages of adverse events are 
higher in the present study compare to other study group. 
 
 
 
 
 
 
 
 
 
116 
 
 
 
Table 16: Adverse events in such groups (no resolution group) and 
  in hospital mortality 
 
 
 
 
 
No resolution group 
 
 
Schroder 
et al.,27 1995 
(n=1398) 
 
 
 
Anderson et al.,44 
2002 (n=2352) 
 
 
 
Present study, 
2014 (n=60) 
 
 
LVF 
 
 
32% 
 
 
23.3% 
 
 
77% 
 
 
Cardiogenic shock 
 
 
17% 
 
 
6.7% 
 
 
55% 
 
 
Arrhythmias 
 
 
24% 
 
 
NA 
 
 
44.4% 
 
 
Recurrent angina 
 
 
14% 
 
 
40% 
 
 
33.3% 
 
 
Inhospital mortality 
 
 
18% 
 
 
6.6% 
 
 
66.7% 
 
 
 
 
Most frequent adverse event in no resolution group in the present study, LVF 
followed by cardiogenic shock. Even in other study groups LVF is the most 
frequent adverse event. But percentages of adverse events in the present study 
group are higher compare to other study groups. In hospital mortality in the 
present study group is 66.7% which is also high when compared to other study 
groups. 
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SUMMARY 
 
 This study is a prospective study with sample size of 60 patients admitted 
to IMCU, Thanjavur Medical college Hospital, during the period from 
December 2013-  August 2014 
 
 Mean age of population studied is 50.7 9.6. 
 
 
 Male to female ratio 4:1 shows a clear male preponderance. 
 
 Chest pain the is most common mode of presentation seen in 95% of 
cases, followed by sweating and breathlessness. 
 
 Smoking is the most common risk in the present study, followed by 
hypertension and diabetes respectively. 
 
 Anterior wall MI constitutes 58.3% compared to inferior wall MI 41.7%. 
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 Based on percentage of ST segment resolution after 90 minutes of 
thrombolysis. Patients divided into three categories. Patients with > 
70% ST resolution (complete STR) constitute 41.7%, patients with 30-
70% ST resolution (partial STR) constitutes 43.3%, patients with < 
30% ST resolution (no STR) constitutes only 15%. 
 
 
 Patients with > 70% ST resolution (complete STR) associated with 
less frequent adverse events during hospital stay and less inpatient mortality. 
 
 Patients with 30-70% ST resolution (partial STR) associated with mor 
frequent adverse events during hospital stay when compared to complete 
STR group, but less frequent adverse events when compared to No STR 
group. 
 
 Patients with < 30% ST resolution (no STR group) were associated with 
more frequent adverse events and in hospital mortality. 
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 Among adverse events, left ventricular failure is most frequent adverse 
events seen in 33.3% cases, followed by arrhythmias 26.7% cases 
recurrent angina 18.3% cases and cardiogenic shock 8.3% cases. 
 
 
 Inpatient mortality seen in 7 cases that is 11.7% cases. Most common 
causes of death are cardiogenic shock 71.4% cases followed by VT / VF 
28.6% cases. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
120 
 
 
 
 
 
 
LIMITATIONS OF THE STUDY 
 
 
 
 
 Sample size is small only 60. 
 
 ST segment after acute myocardial infarction is dynamic and use of static 
measurement could have led to errors in labelling of patients as successful a 
failed reperfusion. 
 
 In the present study, only short term outcome assessed in the form of in 
hospital adverse events and in hospital mortality. 
 
 Study findings were not correlated with coronary angiography and 
nuclear imaging which were gold standard investigation for estimating 
coronary artery patency and myocardial perfusion respectively. 
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CONCLUSION 
 
Patients who were thrombolyzed earlier had better ST segment resolution and better 
outcome than who were thrombolyzed later. 
 
Patients with no resolution of ST segment 90 minutes following thrombolysis 
were associated with more frequent adverse events and increased mortality 
compared to partial and complete resolution group. 
 
Percentage of resolution of ST segment following 90 minutes of thrombolysis as a 
diagnostic test helps in risk stratification of patients. 
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PROFORMA 
1. PRELIMINARY DATA: 
Name :   Religion : 
Age :     Address : 
Sex : 
Income :    I.P. No : 
Occupation :    D.O.A : 
2. PRESENTING COMPLAINTS: 
  Chest pain 
  Syncopal attacks 
  Dyspnoea 
  Shock 
  Palpitation .  
  Other symptoms 
  Giddiness 
  Sweating, Vomiting, Nausea, Haemoptysis,  
 
3. HISTORY OF PRESENTING ILLNESS: 
Chest Pain 
 Site  Precordium   retrosternal    epigastric   elsewhere      
Radiation  
-  sudden Onset     Aggravating/ Precipitating factor 
- Duration     - Relieving factors 
- Character     - Associated symptoms 
 
Dyspnoea 
- Mode of onset     - Exertional or at rest 
- Grade      - H/o P.N.D. 
- H/o Orthopnoea     - H/o Haemoptysis 
- Associated Symptoms 
 
Palpitation 
– Mode of onset     - Exertional or at rest 
– Consciousness of irregularity 
– H/o taking any drugs 
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4. PAST HISTORY 
- H/o anginal attacks     - H/o R.H.D 
- H/o suggestive of M.I    - H/o exposure to V.D 
- H/o Hypertension          Diabetes      Renal disease           CAHD 
 
 
5. PERSONAL HISTORY: 
- Diet - Vegetarian or Non-vegetarian 
- Habits - Smoking,   Alcohol             Tobacco 
 
6. FAMILY HISTORY: 
- Married or single -    H/o Diabetes mellitus 
- Number of children -   H/o Hypertension 
- H/o CAHD  in the family              H/o early and / or sudden death 
 
7. SOCIO-ECONOMICAL AND OCCUPATIONAL HISTORY 
- Occupation - Executive / Clerical / Labour 
- Home environment and surroundings 
 
8. TREATMENT HISTORY: 
 
9. GENERAL PHYSICAL EXAMINATION: 
- General Condition - Good / Fair / Bad 
- Built - Well / Moderate / Poor 
- Nutrition - Well / Moderate / Poor 
- Presence of sweating 
- Pallor,   Cyanosis,   Jaundice,   Clubbing,   Oedema.   Lymphadenopathy 
- Xanthomas      
- Any external congenital anomalies,  
Vital signs 
Temperature 
Pulse -   /min   Rhythm  Volume  Character  Condition of the 
Vessel wall  Radio femoral / Radio radial delay 
Respiratory rate 
Blood Pressure   Right UL   Left UL   supine posture   
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10. EXAMINATION OF Cardio-Vascular System 
J.V.P -  Raised / not raised 
Precordial Examination 
Inspection:  Shape of the chest / any precordial bulging / Apical impulse 
Any Precordial pulsation /  Parsternal heave / Neck Pulsation 
Palpation: Apical impulse – Position  / Character 
Parasternal heave / thrills / palpable sound 
Percussion: Cardiac borders / any other findings 
Auscultation: 
Heart sounds S1, s2, 
Added sounds s3, s4, 
Pericardial rub 
Murmur 
a. Mitral area 
b. Tricuspid area 
c. Aortic area 
d. Pulmonary area 
 
11. EXAMINATION OF R.S. 
 Pulmonary Edema    only Bases  Extensive 
 
12. PER ABDOMEN: 
 
13. EXAMINATION OF C.N.S: 
 
14. INVESTIGATIONS: 
Blood – Hb%  TC   D.C.    E.S.R. 
Fasting lipid profile   FBS   PPBS 
BI. Urea.  S. Creatinine 
Cardiac enzymes   – Trop. T 
Urine – Albumin  - Sugar  - Microscopy 
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Electrocardiogram 
Before Thrombolysis 
Rate     Q.R.S. complex & duration       Rhythm   Q.T. Interval       Axis  
 S.T. Segment 
- P. Wave  - T. Wave  - P.R. Interval  - Any other significant findings 
Sum of ST segment Elevation  
ECG  90 min after start of thrombolysis 
Rate     Q.R.S. complex & duration       Rhythm   Q.T. Interval       Axis  
 S.T. Segment 
- P. Wave  - T. Wave  - P.R. Interval  - Any other significant findings 
Sum of ST segment Elevation  
 
Percentage of ST segment resolution after thrombolysis: 
No STR  < 30%   Partial STR 30-70%   Complete STR More than 70% 
 
Time interval: 
Time of Onset of Chest Pain: 
Time of Start of Thrombolysis: 
  
Chest pain to Thrombolysis time interval CPTT: 
 
15. DIAGNOSIS: 
 
 
16. COARSE OF ILLNESS DURING HOSPITAL STAY 
- No adverse event  Adverse event   Death 
 
17. TYPE OF ADVERSE EVENT 
Left ventricular failure / Recurrent angina / Cardiogenic shock / Arrhythmias / Others 
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STATISTICAL METHODS APPLIED 
 
 
 
 
Descriptives 
 
 
The Descriptives procedure displays univariate summary statistics for several 
 
 
variables in a single table and calculates standardized values (z scores). Variables can 
 
 
be ordered by the size of their means (in ascending or descending order), 
 
 
alphabetically, or by the order in which you select the variables. 
 
 
Frequencies 
 
 
The Frequencies procedure provides statistics and graphical displays that are 
 
 
useful for describing many types of variables. The Frequencies procedure is a good 
 
 
place to start looking at your data. 
 
 
Cross tabs procedure 
 
 
The Crosstabs procedure forms two-way and multiway tables and provides a 
 
 
variety of tests and measures of association for two-way tables. The structure of the 
 
 
table and whether categories are ordered determine what test or measure to use. 
 
 
Independent-Samples T Test 
 
 
The Independent-Samples T Test procedure compares means for two groups of 
 
 
cases. Ideally, for this test, the subjects should be randomly assigned to two groups, 
 
 
so that any difference in response is due to the treatment (or lack of treatment) and not 
 
 
to other factors. 
 
 
 
 
SPSS for windows Version-16 (2007) was employed for statistical analysis. 
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KEY TO MASTER CHART 
 
 
 
 
Symptoms 
 
 
CP  Chest pain 
 
BR  Breathlessness 
 
SY  Syncope 
 
Pal  Palpitation 
 
SW  Sweating 
 
P  Present 
 
A  Absent 
Risk factors 
 
 
HTN  Systemic hypertension 
 
DM  Type 2 Diabetes mellitus 
 
SM  Smoking 
 
PA  Past History of Angina 
 
FH  Family history of IHD 
Pulse 
 
 
R  Regular 
 
I  Irregular 
 
JVP  Jugular venous pressure 
 
N  Normal 
 
I  Increased 
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Heart sounds 
 
 
INT  Intensity 
 
AS  Additional sounds 
 
M  Muffled 
 
N  Normal 
 
KC  Killip class 
Respiratory system 
 
 
N  Normal vesicular breath sounds 
 
BC  Basal crepitation 
 
R  Ronchi 
 
PA  Per abdomen 
 
N  Norm 
 
HM  Hepatomegaly 
 
BMI  Body mass index 
Time lag from chest paint o initiation of thrombolysis 
 
STR  ST segment resolution 
 
N  No resolution 
 
P  Partial resolution 
 
G  Good resolution 
Time lag from onset of symptoms to adverse events 
Adverse event 
LVF  Left ventricular failure 
 
CS  Cardiogenic shock 
 
RA  Recurrent angina 
 
AR  Arrhythmia 
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Outcome 
 
 
NAE  No adverse event 
 
AE  Adverse event 
 
D  Death 
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